Johannes Noe

TL;DR: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK‐positive NSCLC and independent review committee–assessed progression‐free survival were consistent with those for the primary end point.

TL;DR: In this article, the authors performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.

TL;DR: The publisher regrets that this article has been temporarily removed and a replacement will appear as soon as possible in which the reason for the removal will be specified.

TL;DR: Retrospective analyses suggest that the echinoderm microtubule-associated protein-like 4 gene-ALK variant (EML4-ALK) may influence ALK-inhibitor treatment benefit, and alectinib continues to demonstrate superior investigator-assessed PFS versus crizotinib in untreated ALk-positive NSCLC, irrespective of EML4-alk variant.

TL;DR: The results indicate that the in vitro engineered systems can not always predict the behavior in more complex systems such as freshly isolated primary hepatocytes, and selection of substrate, substrate concentration, and in vitro transport system are critical for the conduct of in vitro interaction studies involving individual liver OATP carriers.